Sp714
TREATMENT OF THE PATIENT WITH EARLY PSC: UDCA, ORAL VANCOMYCIN, OR NEITHER
Date
May 8, 2023
Explore related products in the following collection:
Society: AGA
Cholestatic liver diseases (CLDs), including primary biliary cholangitis (PBC) and primary sclerosing cholangitis (PSC), are a group of chronic liver disease which share some common clinical features present a variety of different complications and management decisions. Over the past decade, there has been tremendous progress in understanding the pathophysiology, diagnosis, and treatment of patients with these conditions. The purpose of this Clinical Symposium is to illustrate up-to-date practice guidance of common clinical scenarios in a cased-based approach by leading experts in the field.
Cholestatic liver diseases (CLDs), including primary biliary cholangitis (PBC) and primary sclerosing cholangitis (PSC), are a group of chronic liver disease which share some common clinical features present a variety of different complications and management decisions. Over the past decade, there has been tremendous progress in understanding the pathophysiology, diagnosis, and treatment of patients with these conditions. The purpose of this Clinical Symposium is to illustrate up-to-date practice guidance of common clinical scenarios in a cased-based approach by leading experts in the field.
Presenter
Yale University School of Medicine
Tracks
Related Products
Q&A
Cholestatic liver diseases (CLDs), including primary biliary cholangitis (PBC) and primary sclerosing cholangitis (PSC), are a group of chronic liver disease which share some common clinical features present a variety of different complications and management decisions…
PLACEHOLDER
Perturbations in the gut mucosal immune response contributes to IBD. Non-immune cell popopulations including epithelial and stromal cells also play an important role in intestinal inflammation…
MONITORING OF CALPROTECTIN IN INFLAMMATORY BOWEL DISEASE USING A SWEAT BASED WEARABLE DEVICE
Switching from originator to biosimilar infliximab (IFX) is effective and safe. However, data on multiple switching are scarce. The Edinburgh IBD unit has undertaken three switch programmes: (1) Remicade to CT-P13 (2016), (2) CT-P13 to SB2 (2020), and (3) SB2 to CT-P13 (2021)…
A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL OF PRA023 AS INDUCTION THERAPY IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: ARTEMIS-UC, COHORT 1
Switching from originator to biosimilar infliximab (IFX) is effective and safe. However, data on multiple switching are scarce. The Edinburgh IBD unit has undertaken three switch programmes: (1) Remicade to CT-P13 (2016), (2) CT-P13 to SB2 (2020), and (3) SB2 to CT-P13 (2021)…
